Predictive factors for persistent and late radiation complications in breast cancer survivors.
Breast cancer survivors
Breast pain or swelling
Normal tissue complications
Predictive factors
Radiation late effects
Journal
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
ISSN: 1699-3055
Titre abrégé: Clin Transl Oncol
Pays: Italy
ID NLM: 101247119
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
03
03
2019
accepted:
11
05
2019
pubmed:
28
5
2019
medline:
18
11
2020
entrez:
25
5
2019
Statut:
ppublish
Résumé
With improved diagnostic techniques and treatments of breast cancer, overall survival times are longer, giving more opportunity for normal tissue complications of treatment to manifest. Radiation late effects (RLEs) could have profound long-term impacts on the quality of life of the survivors. The aim of this study was to identify predictive factors influencing timing and types of complications in patients referred to the Adult Radiation Late Effects Clinic (ARLEC). In a period of 16 years, 296 breast cancer patients were referred to the ARLEC. The clinical records were retrospectively studied to collect epidemiologic, medical and treatment data. Associations were sought between candidate predictive factors and time to the first complication after radiation treatment (RT) completion (primary outcome), and pain or swelling (secondary outcomes) using univariable and multivariable linear and logistic regression analyses. All analyses were performed in SAS, version 9.4. All patients were female with a mean age of 56.3 years. The first treatment-related complication occurred after a median of 3 months. Patients were followed at ARLEC for a median of 18 months. Older age and delay from surgery to RT (S-RT delay) were associated with earlier onset of complications (both p < 0.001). The most common complications were breast pain (62.1%) and swelling (45.9%). Histology and RT boost were associated with pain (p = 0.035 and 0.013). RT boost and S-RT delay on the other hand were associated with swelling (p = 0.013 and 0.005). Clinical factors identified could help recognize the patients at high risk for developing RLEs and alert physicians to initiate earlier diagnostic and therapeutic measures.
Identifiants
pubmed: 31123988
doi: 10.1007/s12094-019-02133-8
pii: 10.1007/s12094-019-02133-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
360-369Subventions
Organisme : Princess Margaret Cancer Foundation
ID : FCC 886471001147
Références
Arch Surg. 1991 Nov;126(11):1336-41; discussion 1341-2
pubmed: 1747046
Am J Physiol Heart Circ Physiol. 2014 May 15;306(10):H1426-34
pubmed: 24633552
Radiother Oncol. 2002 May;63(2):129-45
pubmed: 12063002
Breast Cancer Res Treat. 2011 May;127(1):171-7
pubmed: 21384167
J Contemp Brachytherapy. 2012 Dec;4(4):219-26
pubmed: 23378851
J Natl Cancer Inst. 2002 Aug 7;94(15):1143-50
pubmed: 12165639
N Engl J Med. 1993 Jun 3;328(22):1587-91
pubmed: 8387637
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Strahlenther Onkol. 2005 Oct;181(10):625-31
pubmed: 16220400
Rep Pract Oncol Radiother. 2016 May-Jun;21(3):225-31
pubmed: 27601955
Breast Cancer Res Treat. 2013 Jan;137(2):617-30
pubmed: 23242613
Pathol Oncol Res. 2012 Apr;18(2):421-7
pubmed: 21984131
Breast J. 2014 Jan-Feb;20(1):9-14
pubmed: 24224885
Eur J Surg Oncol. 2011 Feb;37(2):116-21
pubmed: 21130597
Rev Neurol (Paris). 2012 Dec;168(12):939-50
pubmed: 22742890
Ann Surg Oncol. 2015 Apr;22(4):1140-5
pubmed: 25319575
Radiother Oncol. 2004 Nov;73(2):119-31
pubmed: 15542158
N Engl J Med. 1993 Jun 3;328(22):1581-6
pubmed: 8292119
Br J Cancer. 2005 Jan 31;92(2):225-30
pubmed: 15655557
Radiol Oncol. 2012 Dec;46(4):284-95
pubmed: 23412910
J Clin Oncol. 2003 Jul 1;21(13):2545-50
pubmed: 12829674
Crit Rev Oncog. 2018;23(1-2):69-92
pubmed: 29953368
Pain Med. 2009 May-Jun;10(4):708-15
pubmed: 19453965
Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):1220-7
pubmed: 20971571
Breast Cancer Res Treat. 2007 Nov;106(1):143-50
pubmed: 17221151
Pain. 1999 Oct;83(1):91-5
pubmed: 10506676
Radiother Oncol. 2012 Dec;105(3):273-82
pubmed: 23245644
Acta Oncol. 2004;43(6):551-7
pubmed: 15370612
Semin Radiat Oncol. 2003 Jul;13(3):274-89
pubmed: 12903016
EBioMedicine. 2015 Oct 25;2(12):1965-73
pubmed: 26844275
N Engl J Med. 2010 Feb 11;362(6):513-20
pubmed: 20147717
Nat Rev Cancer. 2009 Feb;9(2):134-42
pubmed: 19148183
Clin Breast Cancer. 2018 Oct;18(5):e899-e908
pubmed: 29550285
Breast Cancer Res Treat. 2012 Aug;134(3):915-22
pubmed: 22415476
Oncologist. 2011;16 Suppl 1:20-2
pubmed: 21278437
J Pain. 2011 Jul;12(7):725-46
pubmed: 21435953
Korean J Radiol. 2009 Sep-Oct;10(5):496-507
pubmed: 19721835
Acta Oncol. 1994;33(2):139-57
pubmed: 8204269
J Endocrinol Invest. 1998 Mar;21(3):160-5
pubmed: 9591211
Int J Radiat Oncol Biol Phys. 1991 Jul;21(2):361-7
pubmed: 1648044
Clin Oncol (R Coll Radiol). 2011 Dec;23(10):662-73
pubmed: 21646002
Cancer. 1998 Dec 15;83(12 Suppl American):2788-97
pubmed: 9874399
Cell Signal. 2013 Jan;25(1):264-8
pubmed: 23063463
N Engl J Med. 1995 Nov 30;333(22):1456-61
pubmed: 7477145
Ann Surg Oncol. 2013 Oct;20(11):3453-60
pubmed: 23702642
Breast J. 2004 Sep-Oct;10(5):405-11
pubmed: 15327493
Transl Cancer Res. 2012 Jun;1(1):35-48
pubmed: 22866245
J Clin Oncol. 1999 Aug;17(8):2326-33
pubmed: 10561294
Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1209-15
pubmed: 12654429
JAMA. 2009 Nov 11;302(18):1985-92
pubmed: 19903919
Cancer. 2017 Jun 1;123(11):1925-1934
pubmed: 28117882
Cancer Radiother. 2013 Oct;17(5-6):355-62
pubmed: 23969245
Cancer. 1982 Jun 1;49(11):2295-9
pubmed: 7074546
Breast Cancer Res Treat. 2014 Oct;147(3):463-71
pubmed: 25164973
Nat Rev Cancer. 2006 Sep;6(9):702-13
pubmed: 16929324
Eur J Cancer. 2008 Nov;44(17):2587-99
pubmed: 18757193